34th week of 2015 patent applcation highlights part 8 |
Patent application number | Title | Published |
20150231091 | METHODS AND USE OF INDUCING APOPTOSIS IN CANCER CELLS - The present disclosure relates to a method of inducing apoptosis in a cancer cell by delivery of exogenous Coenzyme Q10 or its metabolites thereof in a pharmaceutically acceptable carrier to effectuate cell contact of endogenous Coenzyme Q10 or its metabolites thereof in addition to but not limited to mevalonic acid and oleic acid to form an intracellular complex. The present disclosure also provides a method of modulating the p53 pathway and Bcl-2 protein family in a manner that restores the apoptotic potential to a cancer cell by delivery of Coenzyme Q10 in a pharmaceutically acceptable carrier. The present disclosure further provides a method to specifically normalize the ratio of pro-apoptotic and anti-apoptotic members of the Bcl-2 gene family in a proportion to re-program a cancer cell to undergo apoptosis. | 2015-08-20 |
20150231092 | NOVEL EFFERVESCENT SACHET FORMULATIONS OF DAPOXETINE AND A PDE5 INHIBITOR - The present invention relates to novel effervescent sachet formulations of dapoxetine or a pharmaceutically acceptable salt thereof and a phosphodiesterase type 5 inhibitor or a pharmaceutically acceptable salt thereof. The present invention further relates to a process for preparing such a formulation and to the use thereof in the treatment of erectile dysfunction. | 2015-08-20 |
20150231093 | METHODS AND COMPOSITIONS FOR COUNTERMEASURES AGAINST RADIATION - Described are methods and compositions for treating subjects for symptoms from unplanned radiation or protecting subjects therefrom. Embodiments include methods of treating subjects exposed to unplanned radiation with pharmaceutical compositions comprising a biguanide compound. In further embodiments, methods and compositions are provided for radioprotection by administering pharmaceutical compositions comprising a biguanide compound and additional therapeutic compounds. | 2015-08-20 |
20150231094 | DEVICES, METHODS, AND COMPOSITIONS FOR CONTROLLING INFECTIONS - The subject invention provides novel and highly effective methods and devices for convenient and effective wound irrigation. | 2015-08-20 |
20150231095 | Antimicrobial compositions and uses therefore - Provided are compositions having at least one buffering agent, at least one chelating agent and at least one antimicrobial agent, which can be used for treating and/or preventing diseases or disorders in a variety of animals. In certain embodiments, in particular, the compositions can be used for treating and/or preventing ophthalmic and oral cavity diseases or disorders in humans and animals. | 2015-08-20 |
20150231096 | COMBINATION THERAPIES USING HDAC INHIBITORS - The present invention pertains to a method for treating cancer, such as lung cancer, multiple myeloma, lymphoma, and epithelial ovarian cancer, comprising the administration to a patient in need thereof a first amount or dose of a histone deacetylase (HDAC) inhibitor, such as PXD-101, and a second amount or dose of another chemotherapeutic agent, such as dexamethasone or 5-fluorouracil, or an epidermal growth factor receptor (EGFR) inhibitor, such as TarcevaÚ, wherein the first and second amounts or doses together comprise a therapeutically effective amount. | 2015-08-20 |
20150231097 | COMPOUND TO PREVENT OR TREAT CONTACT DERMATITIS CAUSED BY POISONOUS PLANTS - Poisonous plants release urushiol, an oil that can cause dermatitis or irritation of the skin. A compound to alleviate symptoms of a poison plant rash is disclosed. The compound an anti-itch agent to soothe the skin and prevent scratching and a chemical peel agent to remove the urushiol from the skin. The compound can optionally further include alcohol or a hand sanitizer. | 2015-08-20 |
20150231098 | ANTISEPTIC, ANTISEBORRHEIC, EXFOLIATING COMPOSITION FOR GETTING RID OF OR PREVENTING ACNE - The invention refers to an antimicrobial, exfoliating and seboregulating hydrosoluble composition comprising a combination of diallyl disulphide modified oxide (DDMO) and alpha hydroxyethanoic acid (glycolic acid), which acts removing bacteria affecting the skin including those caused by acne, said composition also provides deep cleansing, exfoliating action, reduces epidermal cohesion facilitating cellular change, preventing the occurrence of several forms of acne in the skin and additionally producing seboregulating effects by avoiding blockage of sebaceous glands. | 2015-08-20 |
20150231099 | Sodium Ibuprofen Tablets and Methods of Manufacturing Pharmaceutical Compositions Including Sodium Ibuprofen - Sodium ibuprofen compositions and methods of manufacturing tablets and caplets comprising sodium ibuprofen are described. The formulation is advantageous because it allows for the formation of tablets having low sodium content and further provides tablets exhibiting improved physical stability, high tablet hardness and high strength, coupled with excellent dissolution and bioavailability characteristics. The formulations and processes are further advantageous because they can be produced in large quantities without an unacceptable number of defective tablets. | 2015-08-20 |
20150231100 | COMPOSITION FOR PREVENTING OR TREATING EYE DISEASES, CONTAINING S-ALLYL-L-CYSTEINE AS ACTIVE INGREDIENT, AND PHARMACEUTICAL FORMULATION CONTAINING SAME - Disclosed is a composition for preventing or treating eye diseases. The composition for preventing or treating eye diseases contains S-allyl-L-cysteine, a pharmaceutically acceptable salt thereof, or a solvate or a hydrate thereof as an active ingredient, and may inhibit photo-oxidation. The composition for preventing or treating eye diseases inhibits the accumulation of A2E in retinal pigment epithelial cells and the oxidation of A2E, thereby remarkably preventing or treating eye diseases including age-related macular degeneration or degenerative retinal disorder. | 2015-08-20 |
20150231101 | SOLID PHARMACEUTICAL PREPARATION CONTAINING LEVOTHYROXINE - The invention relates to a solid pharmaceutical preparation comprising levothyroxine sodium, gelatine, citric acid and a filler. The solid pharmaceutical preparation has an improved stability. | 2015-08-20 |
20150231102 | METHODS OF TREATING MIXED DYSLIPIDEMIA - The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate. | 2015-08-20 |
20150231103 | METHOD FOR MANUFACTURING REFINED CHLOROGENIC ACIDS COMPOSITION - Provided is a method for producing a chlorogenic acids composition having a reduced caffeine content and good taste and favor, capable of efficiently recovering high purity of chlorogenic acids from a chlorogenic acids-containing composition. The method for producing a purified chlorogenic acids composition comprises a step A of bringing a chlorogenic acids-containing composition into contact with a cation exchange resin; a step B of bringing the liquid obtained in the step A into contact with an anion exchange resin; and a step C of bringing an eluent into contact with the anion exchange resin after the step B. | 2015-08-20 |
20150231104 | SMALL MOLECULE INHIBITORS OF REPLICATION PROTEIN A THAT ALSO ACT SYNERGISTICALLY WITH CISPLATIN - Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 μM. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC50 values below 3 μM. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy. | 2015-08-20 |
20150231105 | METHOD FOR TREATING A CANCER CAUSED BY CANCER STEM CELLS - This invention provides a method for inhibiting tumor growth caused by cancer stem cells in a subject in need thereof, which comprises administering to the subject an effective amount of 4-acetyl-antroquinonol B. | 2015-08-20 |
20150231106 | 3-METHANESULFONYLPROPIONITRILE FOR TREATING INFLAMMATION AND PAIN - The present invention relates to purified 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt thereof, and a method for preparing such compound. The compound has at least 90% (w/w) purity. The present invention is also directed to a pharmaceutical composition comprises the purified compound and a pharmaceutically acceptable carrier. The present invention is further directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering 3-methanesulfonylpropionitrile or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof. | 2015-08-20 |
20150231107 | ORGANOARSENIC COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER - A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R | 2015-08-20 |
20150231108 | Cannabinoid Inhaler and Composition Therefor - The present invention provides a cannabinoid inhaler, compositions, and methods for delivering a cannabinoid composition to a subject. The cannabinoid composition is delivered in the form of inhaled droplets of respirable size via pulmonary administration. The invention may be used in the treatment of a condition or disorder selected from the group consisting of neuropathic pain, cannabis addiction, nausea, motion sickness, arthritis, and neurodegenerative disease. | 2015-08-20 |
20150231109 | COMBINATIONS (CATECHINS AND METHOTREXATE) FOR USE IN THE TREATMENT OF MELANOMAS - The invention provides a method of treatment of melanoma comprising administering a tyrosinase expression enhancer, such as MTX, and a tyrosinase-activated prodrug, such as TMECG or TMCG, to an individual in need thereof. Also provided is a method of treating melanoma comprising administering a tyrosinase-activated prodrug and a compound for differentiating a stem-like tumor cell into a matured cell that is a tyrosinase producer to an individual in need thereof. Further provided is a method of treatment of melanoma comprising administering a tyrosinase expression enhancer and a tyrosinase-activated prodrug to an individual in need thereof, wherein the individual has a melanoma in which one or more of BRAF, NRAS, p53, GNAQ, EGFR, PDGFR, RAC or c-kit carries a mutation. | 2015-08-20 |
20150231110 | TREATMENT OF OBSTRUCTIVE SLEEP APNEA SYNDROME WITH A COMBINATION OF A CARBONIC ANHYDRASE INHIBITOR AND AN ADDITIONAL ACTIVE AGENT - This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine. | 2015-08-20 |
20150231111 | METHODS OF TREATING SKIN CONDITIONS USING CYCLOLIGNAN COMPOUNDS - The present invention includes compositions and methods for the treatment of skin conditions by administration of a cyclolignan such as picropodophyllin and/or a derivative, metabolite, analog, prodrug, pharmaceutically acceptable salt, or hydrate thereof. | 2015-08-20 |
20150231112 | NASAL AND SINUS WASH COMPOSITIONS AND METHODS - Nasal and sinus cavity wash compositions containing magnesium ascorbate and, optionally, a bicarbonate salt, are provided to cleanse the nasal and sinus cavities of a subject and to reduce nasal and sinus irritation, including inflammation. | 2015-08-20 |
20150231113 | USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS - There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone. | 2015-08-20 |
20150231114 | 3-CYCLOALKYLAMINOPYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS - The present invention relates to 3-cycloalkylaminopyrrolidine derivatives of the formula I: | 2015-08-20 |
20150231115 | METHODS OF TREATING AN INFLAMMATORY-RELATED DISEASE - The invention relates to pharmaceutical compositions and methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA. Preferably the pharmaceutical composition comprises one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, an anti-inflammatory agent, and a pharmaceutically acceptable carrier. | 2015-08-20 |
20150231116 | Methods Of Treating Dyskinesia And Related Disorders - The present disclosure describes compounds and pharmaceutically acceptable salts thereof and compositions and formulations comprising the same that are useful in methods of treating dyskinesia or related disorders, and methods for treating dyskinesia or related disorders. | 2015-08-20 |
20150231117 | ARRY-520 FOR USE IN TREATING CANCER IN A PATIENT WITH LOW AAG - The compound ARRY-520 for use for treating cancer in patients with low [AAG] is provided. | 2015-08-20 |
20150231118 | TETRAHYDROCARBOLINE DERIVATIVE - An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. | 2015-08-20 |
20150231119 | Azaindoles As Respiratory Syncytial Virus Antiviral Agents - Azaindoles having inhibitory activity on RSV replication and having the formula I | 2015-08-20 |
20150231121 | POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR - The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor. | 2015-08-20 |
20150231122 | ANTICHOLINERGIC NEUROPROTECTIVE COMPOSITION AND METHODS - The present invention relates to a pharmaceutical composition comprising propiverine, trospium or glycopyrrolate; and a non-anticholinergic antiemetic agent. It is also related to a pharmaceutical composition comprising a high dose of solifenacin or a pharmaceutically acceptable salts thereof; and a non-anticholinergic antiemetic agent. Pharmaceutical compositions containing high dose of nsPAChA for use for increasing the AChEI blood concentrations and for combating neurodegeneration are also described. The invention also relates to a method for inducing neuroprotection and combating neurodegeneration in a patient suffering from Alzheimer type dementia as well as to a method for increasing the blood levels of an acetyl choline esterase inhibitor (AChEI) in a human subject treated with an AChEI dose. | 2015-08-20 |
20150231123 | COMPOSITIONS, METHODS AND USES FOR THE TREATMENT OF DIABETES AND RELATED CONDITIONS BY CONTROLLING BLOOD GLUCOSE LEVEL - The present invention relates to compositions and methods for controlling glycaemia in a mammalian in need thereof. The present invention relates to compositions and methods for the treatment of diabetes disease and related disorders. More specifically, the present invention relates to novel therapies or combinatorial therapies of diabetes and related disorders, based on compositions controlling the blood glucose level. | 2015-08-20 |
20150231124 | PHARMACEUTICAL COMBINATION COMPRISING A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR AND/AN AROMATASE INHIBITOR - The present invention relates to a pharmaceutical combination comprising a 2-carboxamide cycloamino urea derivative compound of formula (I) and at least one aromatase inhibitor for the treatment of cancer; the uses of such combinations in the treatment of cancer; and to a method of treating warm-blooded animals including humans suffering cancer by administering to said animal in need of such treatment an effective dose of a 2-carboxamide cycloamino urea derivative compound of formula (I) in combination with at least one aromatase inhibitor. | 2015-08-20 |
20150231125 | Compositions for Treatment of Attention Deficit Hyperactivity Disorder - Therapeutic compositions and methods for treatment of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD) include dosage forms that deliver a therapeutic amount of active drug in a delayed and controlled release formulation. The dosage form can be administered at night and drug release is delayed for from 4 to 6 hours or longer, followed by an ascending release rate. | 2015-08-20 |
20150231126 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS - Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown induce a rapid onset of antipsychotic action and increase the responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic. | 2015-08-20 |
20150231127 | BITOPIC MUSCARINIC AGONISTS AND ANTAGONISTS AND METHODS OF SYNTHESIS AND USE THEREOF - Compositions for treating a condition associated with activity of a muscarinic receptor (e.g., one or more of M | 2015-08-20 |
20150231128 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS - The present invention relates to a method for treating skin diseases and skin conditions in a patient in need thereof which comprises of administering a therapeutically effective amount of a pharmaceutical composition comprising a therapeutically effective amount of 7-(1H-Imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or its individual enantiomers or the tautomers thereof, or a pharmaceutically acceptable salt thereof. | 2015-08-20 |
20150231129 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING SYMPTOMS OF HORMONAL VARIATIONS - The present invention relates to methods, compositions, and kits for treating or preventing symptoms of hormonal variation. The method comprises the steps of administering an effective amount of Dextromethorphan or Dextrorphan, or a pharmaceutically acceptable salt thereof, to a subject having one or more symptoms of hormonal variations. | 2015-08-20 |
20150231130 | PHARMACEUTICAL COMPOSITION COMPRISING DIAMORPHINE FOR INTRANASAL ADMINISTRATION - The invention provides a method of assembling a device and a kit suitable for administration to multiple patients comprising a multi-dose pharmaceutical composition of nasal analgesic in the form of a nasal spray. The present invention also provides a method for reducing the respiratory depressant effect associated with diamorphine administration, the method comprise a single dose pharmaceutical composition comprising lyophilized diamorphine and a diluent for reconstitution, wherein the dose of diamorphine is 0.1 mg/kg body weight. | 2015-08-20 |
20150231131 | ONCE-A-DAY OXYCODONE FORMULATIONS - The invention is directed to sustained release formulations containing oxycodone or a pharmaceutically acceptable salt thereof which provide a mean C | 2015-08-20 |
20150231132 | PROCASPASE-ACTIVATING COMPOUNDS AND METHODS - The invention provides compounds and compositions useful for the modulation of certain enzymes. The compounds and compositions can induce of cell death, particularly cancer cell death. The invention also provides methods for the synthesis and use of the compounds and compositions, including the use of compounds and compositions in therapy for the treatment of cancer and selective induction of apoptosis in cells. | 2015-08-20 |
20150231133 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF INFLUENZA, COMMON COLD AND INFLAMMATION - The embodiments described herein include methods and formulations for treating influenza, common cold and associated acute inflammation. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2015-08-20 |
20150231134 | Combination Therapy using Belinostat and Trabectedin - The present invention relates generally to therapies for the treatment of diseases and disorders that are mediated by histone deacetylase (HDAC) (for example, cancer, including, for example, ovarian cancer, soft-tissue sarcoma, osteosarcoma, etc.) which employ a combination (e.g., a synergistic combination) of (a) belinostat, or a salt, hydrate, or solvate thereof, and (b) trabectedin, or a salt, hydrate, or solvate thereof. | 2015-08-20 |
20150231135 | FAK INHIBITORS - A compound of the formula (I): | 2015-08-20 |
20150231136 | MDM2 INHIBITORS FOR TREATMENT OF OCULAR CONDITIONS - Provided herein are pharmaceutical compositions for the treatment of various ocular diseases characterized by unwanted cellular proliferation. The pharmaceutical compositions may comprise one or more MDM2 inhibitors, and may further comprise one or more additional therapeutic agents. Also provided are methods of use of MDM2 inhibitors and/or formulations thereof for the treatment of ocular diseases characterized by unwanted cellular proliferation. | 2015-08-20 |
20150231137 | METHOD OF TREATING CANCER - Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923. | 2015-08-20 |
20150231138 | SULFUR-CONTAINING BICYCLIC COMPOUND - A sulfur-containing bicyclic compound of the present invention has a PAM action of GABA | 2015-08-20 |
20150231139 | THERAPY FOR CONSTIPATION - A method is disclosed of treating acute, sub-acute or chronic constipation in a patient having a condition requiring such treatment. The method includes administering a lipase inhibitor. Also provided is a method of treating chronic pain in a patient which includes administration of a lipase inhibitor, with or without pain medication. | 2015-08-20 |
20150231140 | METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS - Disclosed herein are methods of treating a patient suffering from a cognitive disorder using the following compounds: | 2015-08-20 |
20150231141 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF - The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, | 2015-08-20 |
20150231142 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases - The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions. | 2015-08-20 |
20150231143 | Heteroaryl Derivatives as Alpha7 NACHR Modulators - Disclosed is a compound of formula I: | 2015-08-20 |
20150231144 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure | 2015-08-20 |
20150231145 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF DRUG ADDICTION - This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/mL to about 850 ng/mL (AUC/24 h) under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-08-20 |
20150231146 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF DRUG ADDICTION - This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of 50 ng/mL to 180 ng/mL (AUC/24 h) under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-08-20 |
20150231147 | METHODS FOR ACUTE AND LONG-TERM TREATMENT OF DRUG ADDICTION - This invention is directed to a method of treating opioid or opioid-like drug addiction, including acute and post-acute withdrawal symptoms, comprising treating an addicted patient with noribogaine at a dosage that provides an average serum concentration of about 50 ng/mL to about 180 ng/mL under conditions where the QT interval prolongation does not exceed about 50 milliseconds. | 2015-08-20 |
20150231148 | TARGETING PRIMARY CILIA TO TREAT GLAUCOMA - Methods for reducing intraocular pressure and treating glaucoma are disclosed. The methods include administering to an individual a composition comprising a TRPV4 agonist. | 2015-08-20 |
20150231150 | SUBSTITUTED PORPHYRINS - The present invention relates, in general, to a method of modulating physiological and pathological processes and, in particular, to a method of modulating cellular levels of oxidants and thereby processes in which such oxidants are a participant. The invention also relates to compounds and compositions suitable for use in such methods. | 2015-08-20 |
20150231151 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - In some embodiments, the present disclosure pertains to a composition for modulating the expression of at least one gene associated with neuronal cell survival or stability. In some embodiments, the present disclosure provides for compositions for the treatment of neurodegenerative diseases comprising one or more phosphate complexes of platinum of the formulas I, II, III and IV as set forth in FIG. | 2015-08-20 |
20150231152 | FLUOROALKYL AND FLUOROCYCLOALKYL 1,4-BENZODIAZEPINONE COMPOUNDS - Disclosed are compounds of Formula (I): (Formula (I)) wherein: R | 2015-08-20 |
20150231153 | FULVESTRANT FORMULATIONS - The invention provides a fulvestrant composition comprising a pharmaceutically acceptable alcohol, polysorbate 80, an antioxidant, and castor oil, which is substantially or completely free of a non-aqueous ester solvent and which demonstrates excellent storage stability. The composition may be used to treat hormone receptor positive metastatic breast cancer in a subject. | 2015-08-20 |
20150231154 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING NORELGESTROMIN FOR CONTRACEPTION AND HORMONE REPLACEMENT - The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy. | 2015-08-20 |
20150231155 | ONAPRISTONE POLYMORPHIC FORMS AND METHODS OF USE - Polymorphic forms of onapristone and methods of making and using such polymorphic forms are provided. Crystalline polymorphic forms can be characterized by their X-ray powder diffraction patterns and other properties. | 2015-08-20 |
20150231156 | CORTICOSTEROID COMPOSITIONS - Provided herein are methods for treating, preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention. | 2015-08-20 |
20150231157 | CASEIN MICELLES FOR NANOENCAPSULATION OF HYDROPHOBIC COMPOUNDS - The present invention relates to the field of food technology and delivery of hydrophobic biologically active compounds, particularly nutrients, via food products and beverages. In particular the present invention provides isolated casein micelles useful for the encapsulation of hydrophobic nutrients, therapeutic and cosmetic compounds, compositions thereof and methods of preparing the micelles. | 2015-08-20 |
20150231158 | NOVEL OXIME DERIVATIVES AS SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTOR MODULATORS - The present invention relates to novel oxime derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2015-08-20 |
20150231159 | METHODS FOR INCREASING BRAIN FUNCTIONALITY USING 2-FUCOSYL-LACTOSE - Disclosed are methods for enhancing learning and/or memory, enhancing memory acquisition, memory retention and recall by inducing a higher long-term potentiation in hippocampal neuronal synapsis in individuals. The methods include administration of 2-fucosyl-lactose to an individual. | 2015-08-20 |
20150231160 | RAPID-ACTING INSULIN FORMULATION COMPRISING AN OLIGOSACCHARIDE - A composition in aqueous solution, including an insulin and at least one oligosaccharide whose average degree of polymerization is between 3 and 13 and whose polydispersity index PDI is above 1.0, the oligosaccharide having partially substituted carboxyl functional groups, the unsubstituted carboxyl functional groups being salifiable. | 2015-08-20 |
20150231161 | Composition for Preventing or Alleviating Atopic Dermatitis Comprising Immunosuppresent and Transglutaminase 2 Inhibitor - The present invention relates to a composition for preventing, treating or alleviating atopic dermatitis comprising an immunosuppressant and a transglutaminase 2 inhibitor as active ingredients. Conjoint administration of an immunosuppressant and a transglutaminase 2 inhibitor according to the present invention makes it possible to achieve far better therapeutic effects than with administration of either an immunosuppressant or a transglutaminase 2 inhibitor alone, since there is a reduction in the dose of an immunosuppressant which is difficult to administer for a long time because of side effects and with which, when discontinued, lesions are liable to become exacerbated to the original state, and since an immunosuppressant is mixed with a transglutaminase 2 inhibitor which in some patients has a lacklustre effect in treating atopic dermatitis. | 2015-08-20 |
20150231162 | FRUCTOSE ABSORPTION INHIBITOR - A fructose absorption inhibitor according to the present invention comprises a hydrolyzable tannin as an active ingredient. The hydrolyzable tannin preferably has a form composed of a gallic acid derivative and/or an ellagic acid derivative bound to a hydroxy group in glucose via an ester bond, and includes ellagitannin, gallotannin and so on. | 2015-08-20 |
20150231163 | COMPOSITION FOR PREVENTING OR TREATING COLITIS - The present invention relates to a novel use of an | 2015-08-20 |
20150231164 | SIRTUIN GENE POTENTIATOR, AND PHARMACEUTICAL PRODUCT, COSMETIC PRODUCT, AND FOOD PRODUCT USING SAME - Disclosed are a sirtuin gene potentiator, and a pharmaceutical product, a cosmetic product, and a food product using the same. The sirtuin gene potentiator of the present invention contains a given polyphenol and/or terpenoid as an active component. The polyphenol and/or the terpenoid can be contained in the form of a plant such as pomegranate or a plant extract thereof. The sirtuin gene potentiator of the present invention is available from a familiar material to avoid concerns such as side effects on the human body in advance. Such a sirtuin gene potentiator is useful as a novel material in the fields of pharmaceutical products, cosmetic products, and food products. | 2015-08-20 |
20150231165 | TREATMENT AND PREVENTION OF P. AERUGINOSA INFECTIONS USING COFORMYCIN ANALOGS - Methods and devices are disclosed for treating or preventing infections in a subject due to | 2015-08-20 |
20150231166 | NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS - Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: | 2015-08-20 |
20150231167 | TREATMENT OF HEMATOLOGICAL NEOPLASMS - Hematological neoplasms resistant to treatment with an ATP-competitive inhibitor of BCR-ABL are treated by administration of N | 2015-08-20 |
20150231168 | METHODS FOR SUSTAINED AND REGULATABLE GENE EXPRESSION USING VIRAL BASED EXPRESSION VECTORS - Disclosed are genetic expression cassettes, and vectors comprising them useful for the delivery of isolated nucleic acid segments including those expressing or encoding one or more selected therapeutic constructs (including, without limitation, therapeutic peptides, polypeptides, ribozymes, or catalytic RNA molecules), to one or more selected cells or tissues of a vertebrate animal. Methods employing the disclosed genetic constructs in the development of gene therapy-based viral vector systems are also disclosed. The expression cassettes and viral vectors disclosed herein provide new tools for methods of treating mammalian, and in particular, human diseases, disorders, and/or dysfunctions. The disclosed compositions and methods find particular utility in a variety of investigative, diagnostic, and therapeutic regimens, including, for example, in the treatment or amelioration of symptoms of a variety of mammalian, and particularly, human conditions. | 2015-08-20 |
20150231169 | THERAPEUTIC ANTISENSE OLIGONUCLEOTIDE COMPOSITION FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE - Disclosed herein is a method for the sustained amelioration and/or treatment of ulcerative colitis comprising rectal administration of a compound comprising an antisense oligonucleotide having the sequence 5′-GCCCAAGCTOGCATCCOTCA-3′, ISIS 2302. The method results in a decrease in the indications of ulcerative colitis for an extended period (greater than 90 days) after the conclusion of the administration of the composition. The composition is well tolerated and systemic exposure is minimal. | 2015-08-20 |
20150231170 | WOUND HEALING COMPOSITIONS COMPRISING MICROSPHERES - Pharmaceutical or medical compositions for treating a wound are provided, the composition comprise microspheres as an active ingredient and water as a carrier for said microspheres. In some embodiments, compositions comprising a thickening agent dissolved within the water to form a solution having a specific gravity similar to that of the microspheres are provided. | 2015-08-20 |
20150231171 | NYLON-3 CO-POLYMERS AND SYNTHETIC LUNG SURFACTANT COMPOSITIONS CONTAINING SAME - Non-natural oligomers have recently shown promise as functional analogues of lung surfactant proteins B and C (SP-B and SP-C), two helical and amphiphilic proteins that are critical for normal respiration. The generation of non-natural mimics of SP-B and SP-C has previously been restricted to step-by-step, sequence-specific synthesis, which results in discrete oligomers that are intended to manifest specific structural attributes. Presented herein an alternative approach to SP-B mimicry that is based on sequence-random copolymers containing cationic and lipophilic subunits. These materials, members of the nylon-3 family, are prepared by ring-opening polymerization of β-lactams. The best of the nylon-3 polymers display promising in vitro surfactant activities in a mixed lipid film. Pulsating bubble surfactometry data indicate that films containing the most surface-active polymers attain adsorptive and dynamic-cycling properties that surpass those of discrete peptides intended to mimic SP-B. Attachment of an N-terminal octadecanoyl unit to the nylon-3 copolymers affords further improvements by reducing the percent surface area compression to reach low minimum surface tension. | 2015-08-20 |
20150231172 | TARGETING CANCER WITH METABOLIC THERAPY AND HYPERBARIC OXYGEN - A method of treating cancer using ketogenic diet, while concurrently subjecting the patient to a hyperbaric, oxygen-enriched environment. Optionally, the hyperbaric, oxygen-enriched environment is 100% oxygen at 2.5 ATA absolute. The treatment may further include administering at least 10% ketone supplementation, such as acetoacetate, adenosine monophosphate kinase, 1,3-butanediol, or ketone ester, to the patient. | 2015-08-20 |
20150231173 | METHODS FOR TREATING SKIN IRRITATION - The present invention provides a stabilized hypohalous acid solution (or formulation thereof), which may be conveniently packaged for sale, or stored for later use on demand. The invention further provides methods of making the stabilized hypohalous acid solutions, as well as methods of use for disinfecting mammalian tissue, including wounds and burns, and treating skin irritations, among other uses. | 2015-08-20 |
20150231174 | NANOCERIA FOR THE TREATMENT OF OXIDATIVE STRESS - A process for making nanoparticles of biocompatible materials is described, wherein an aqueous reaction mixture comprising cerous ion, citric acid and ethylenediaminetetraacetic acid in a predetermined ratio, an oxidant, and water is provided along with temperature conditions to directly form, without isolation, a stable dispersion of cerium oxide nanoparticles. These biocompatible cerium oxide nanoparticles may be used to prevent and/or treat oxidative stress related diseases, such as stroke, relapse/remitting multiple sclerosis, chronic-progressive multiple sclerosis, amyotrophic lateral sclerosis, and ischemic reperfusion injury. | 2015-08-20 |
20150231175 | COMPOSITIONS WITH ENHANCED BIOAVAILABILITY AND FAST ACTING INHIBITOR OF GASTRIC ACID SECRETION - The present invention relates to the use of pharmaceutically acceptable zinc salts, preferably water soluble zinc salts alone or optionally, in combination with one or more of a protein pump inhibitor (PPI), H2 blocker, anti- | 2015-08-20 |
20150231176 | Compositions and Methods for the Treatment of Cancers - The present invention provides a formulation comprising dichloroacetate and arsenic trioxide. The present invention also provides a method of treating cancer by administering a therapeutically effective amount of dichloroacetate and arsenic trioxide. | 2015-08-20 |
20150231177 | Methods and Compositions for Controlled and Sustained Production and Delivery of Peroxides and/or Oxygen for Biological and Industrial Applications - Methods and compositions for the controlled and sustained release of peroxides or oxygen to aqueous environments (e.g. a patient's body or circulatory system, or for other applications) or non-aqueous environments, include a material coating or encapsulating hydrogen peroxide, inorganic peroxides or peroxide adducts. In the case of peroxide adducts, and particularly in one type of embodiment, the peroxide adducts should be able to permeate the material, but water, hydrogen peroxide and inorganic peroxides should be able to permeate the material. The methods and compositions that allow the release of oxygen, H | 2015-08-20 |
20150231178 | METHOD AND COMPOSITIONS FOR TREATMENT OF CANCERS - A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the patient is ultrapheresed using a capillary tube ultrafilter having a pore size of 0.02 to 0.05 microns, with a molecular weight cutoff of 120,000 daltons, sufficient to filter one blood volume. The preferred replacement fluid is ultrapheresed normal plasma. The patient is preferably treated daily for three weeks, diagnostic tests conducted to verify that there has been shrinkage of the tumors, then the treatment regime is repeated. The treatment is preferably combined with an alternative therapy, for example, treatment with an anti-angiogenic compound, one or more cytokines such as TNF, gamma interferon, or IL-2, or a procoagulant compound. The treatment increases endogenous, local levels of cytokines, such as TNF. This provides a basis for an improved effect when combined with any treatment that enhances cytokine activity against the tumors, for example, treatments using alkylating agents, doxyrubicin, carboplatinum, cisplatinum, and taxol. Alternatively, the ultrapheresis treatment can be combined with local chemotherapy, systemic chemotherapy, and/or radiation. | 2015-08-20 |
20150231179 | APPLICATION OF STEM CELLS IN THE ORTHODONTIC MAXILLARY EXPANSION - This invention relates to the contributions of the bone marrow—and adipose tissue—derived mesenchymal stem cells applied following the maxillary expansion—a frequently used method for the orthodontic treatment—to the healing of the expanded bone tissues. In the invention, adipose tissue and bone marrow-derived stem cell applications increased the healing and quality of the bones following the maxillary expansion and the applied stem cells were involved in the bone structure. Thus, the relapse following the maxillary expansion treatment was avoided. This application will shorten the treatment period for patients undergoing the maxillary expansion treatment and the patients will not have to use apparatus for a long period of time. | 2015-08-20 |
20150231180 | TRABECULAR MESHWORK STEM CELLS - Provided herein are isolated populations of multipotent stem cells capable of differentiating into trabecular meshwork (TM) cells, methods of obtaining an isolated population of TM cells, and isolated populations of TM cells obtained therefrom. Compositions, kits, and devices comprising the isolated populations of multipotent stem cells or TM cells are also provided herein. Further provided are methods of using the compositions, kits, and devices for decreasing intraocular pressure in an eye, increasing cell density in a trabecular meshwork of an eye, increasing outflow of aqueous humor from an eye, or treating or preventing a medical condition in a subject. | 2015-08-20 |
20150231181 | STEM CELLS AND PANCREATIC CELLS USEFUL FOR THE TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS - Fresh human pancreas tissue can be used as a source of cells whence to identify and select a non-stem cell population that is predisposed to be a source for surrogate pancreatic cells that can be used in treating insulin-dependent diabetes. The progenitors of these surrogate pancreatic cells have no reprogramming genes integrated into their genomes, differentiate to the pancreatic lineage pursuant to a protocol that employs only defined reagents, and are substantially unable to differentiate to the mesodermal lineage. | 2015-08-20 |
20150231182 | CELL SYSTEMS AND METHODS FOR DELIVERING DISEASE-SPECIFIC THERAPIES - Cell systems for delivering disease-specific therapies are provided that include a therapeutic cell combined with a plurality of stromal vascular fraction cells or a stromal vascular fraction cell-derived vasculature. The cell systems can include the therapeutic cells and the stromal vascular fraction cells in a biocompatible matrix or can further combine the therapeutic cells and stromal vascular fraction cells with microvessel fragments. Further provided are methods of treating a disease characterized by missing or defiicent gene products wherein a subject is administered an effective amount of a cell system that includes a therapeutic cell for supplying the missing or deficient gene products and a plurality of stromal vascular fraction cells. | 2015-08-20 |
20150231183 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE - The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated virases, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject. | 2015-08-20 |
20150231184 | LITHIUM STIMULATION OF CORD BLOOD STEM CELL PROLIFERATION AND GROWTH FACTOR PRODUCTION - The present invention provides methods for expanding human umbilical cord blood stem cells and methods for stimulating growth factor production by cord blood stem cells using an in vitro cell culture system comprising a lithium salt. The present invention also provides in vivo methods for enhancing the survival and growth of transplanted cord blood stem cells by treating the cells with a lithium salt prior to transplantation. In vivo methods for reducing rejection of transplanted cord blood stem cells by administering a lithium salt after transplantation are also provided. | 2015-08-20 |
20150231185 | REGENERATION AND REPAIR OF NEURAL TISSUE FOLLOWING INJURY - Methods, pharmaceutical compositions and kits for regenerating or repairing neural tissue, decreasing apoptosis and improving neurological function following injury using human umbilical cord tissue-derived cells are disclosed. | 2015-08-20 |
20150231186 | Method for Selection of Agents Influencing Intestinal Motility Disorders and Pain - A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided. | 2015-08-20 |
20150231187 | NOVEL BACTERIUM AND EXTRACTS OF SAID BACTERIUM AND THE USE OF SAME IN DERMATOLOGY - The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies. | 2015-08-20 |
20150231188 | MEDICAL FOOD FOR FETAL HEALTH DURING GESTATION - Medical foods that create fertility enhancement also improve the health of a fetus or child. Multiple examples demonstrate this in mammals. To maximize this effect, the mother continues to consume the medical food into the gestation period. Both mother and fetus benefit from higher immunity and lower cortisol. Superior colostrum further builds the child's immune system. Good health as an infant foreshadows health advantages in later life. | 2015-08-20 |
20150231190 | COMPOSITIONS COMPRISING SIRAITIA GROSVENORI EXTRACTS AND METHODS FOR THE TREATMENT OF INFECTION - A method for the treatment and/or prophylaxis of a viral infection in a subject is provided wherein the method comprises the steps of providing a therapeutically effective amount of a composition comprising an extract of the fruit of | 2015-08-20 |
20150231191 | PHARMACEUTICAL COMPOSITIONS COMPRISING PLANT EXTRACTS AND METHODS FOR REDUCING DURATION OF A COMMON COLD USING SAME - The present disclosure describes pharmaceutical compositions and methods for reducing duration, intensity, and/or bothersomeness of common colds in humans and for reducing severity or duration of common cold symptoms such as nasal congestion, runny nose, watery eyes, dry/scratchy throat and sneezing in humans exhibiting such symptoms. The compositions herein comprise extracts of at least one of | 2015-08-20 |
20150231192 | COMPOSITION USING SEED OIL EXTRACTS AND PHOSPHOLIPIDS TO ENHANCE ABSORPTION OF CAROTENOIDS AND ASSOCIATED METHODS - A dietary supplement composition is formulated in a therapeutically effective amount to treat the eye of an individual having an eye impairment, including dry eyes. It includes a mixture of a phospholipid and a seed oil extract having an ALA to LA ratio between 1:1 and 6:1, astaxanthin, and at least one carotenoid selected from the group consisting of lutein, trans-zeaxanthin, and meso-zeaxanthin. It is formulated into a single dosage capsule. | 2015-08-20 |
20150231193 | Novel Extracts of Cynara Scolymus, Coffea ssp. And Olea Europaea For The Treatment Of Metabolic Syndrome - Disclosed is a composition comprising: a. | 2015-08-20 |